Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification

Fig. 4

Combination of ABT-700 and chemotherapies exhibits enhanced antitumor activity in preclinical tumor models. a Tumor growth curves of Hs746T gastric cancer treated with ABT-700 in combination with docetaxel. ABT-700 at 10 mg/kg was administered twice a week for the duration of the experiment either alone or in combination. Docetaxel at a dose of 7.5 mg/kg was administered once at the start of dosing either alone or in combination. A human IgG control antibody was used as a negative control agent for ABT-700. Each group had 10 mice; there was no significant difference among the vehicle and isotype control groups; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when compared to the control groups (day 4–11); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or docetaxel single agent and the combination group (day 4–28). b Tumor growth curves of EBC1 xenografts treated with ABT-700 in combination with gemcitabine. Athymic mice with established tumors were treated with ABT-700 at 20 mg/kg by i.p. injections every 21 days during the course of study either alone or in combination. Single dose of gemcitabine at 138.5 mg/kg was given on day 0 either alone or in combination. Each group had 5 mice; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when compared to the control groups (day 6–24); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or gemcitabine single agent and the combination group (day 6–51). c Tumor growth curves of NCI-H441 NSCLC treated with m224G11 in combination with Navelbine. Athymic nude mice with established tumors were treated i.p. either with a loading dose of 2 mg of antibody/mouse and then twice a week with 1 mg of antibody/mouse until Day 33 either alone or in combination. Navelbine was dosed (on D0, D7, and D14) at 8 mg/kg by i.p. injections either alone or in combination. A third group administered with the combination treatment was also included. Each group had 6 mice; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when compared to the control groups (day 3–36); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or navelbine single agent and the combination group (day 3–58). d Tumor growth curves of U87MG glioma treated with m224G11 in combination with TMZ (temozolomide). Athymic nude mice with established tumors were treated i.p. with a loading dose of 2 mg of antibody/mouse and then twice a week with 1 mg of antibody/mouse until Day 33 either alone or in combination. TMZ was given (on D0, D7, and D14) at 5 mg/kg by i.p. injections either alone or in combination. A third group administered with the combine treatment was included. Each group had 6 mice; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when compared to the control groups (day 4–14); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or TMZ single agent and the combination group (day 4–35)

Back to article page